Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B Trial. 1988

Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
Dept. of Medicine, University of Missouri-Columbia, School of Medicine 65212.

Eighty-seven patients with histologically or cytologically proven non-small-cell carcinoma of the lung were treated with 4'-deoxydoxorubicin (DxDx) 30 mg/m2 every 3 weeks. Three responses (4%), all partial, were observed. All responses occurred in patients with large-cell anaplastic lung cancer and none in squamous or adenocarcinoma histologies (P less than 0.01). The durations of partial response for these three responders were 70, 198+ and 209+ days. The side effects noted were predominantly neutropenia, anemia, and weight loss. In three patients, declines in cardiac ejection fraction of 7%, 12%, and 23% occurred after cumulative drug doses of 150 mg/m2, 150 mg/m2, and 233 mg/m2, respectively. 4'-Deoxydoxorubicin had little activity in non-small-cell lung cancer at the dose used in this study.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
May 1991, Investigational new drugs,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
September 1987, Cancer treatment reports,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
November 1985, Cancer treatment reports,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
February 1990, Investigational new drugs,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
January 1993, Cancer chemotherapy and pharmacology,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
January 1983, Cancer treatment reports,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
April 1986, Cancer treatment reports,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
January 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
January 1990, Medical and pediatric oncology,
Q S Ringenberg, and M C Perry, and K J Propert, and C Modeas, and V Hirsh, and R B Weiss, and F Richards, and S Graziano, and M Green
March 1995, The Journal of thoracic and cardiovascular surgery,
Copied contents to your clipboard!